Last updated 2026-06-18
- Raised funding round, Jan 2019
Total raised
—
Last: 2019-01
Stage
Seed
Founded
2018
Headcount
1-10
HQ
, Israel
Sector
Health Tech & Life Sciences
About
Glixogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders that are driven by damage to the neuron's myelin sheath, such as multiple sclerosis (MS). Glixogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1, a novel target that facilitates neuronal remyelination towards modifying the outcome of the disease. Glixogen Therapeutics was founded at the FutuRx biotechnology incubator.
Funding history · 1 round · — total
2019-01
Undisclosed
Q&A
- What is Glixogen Therapeutics' primary focus?
- Glixogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders such as multiple sclerosis (MS).
- What is the status of Glixogen Therapeutics?
- Glixogen Therapeutics is currently inactive, having ceased operations in December 2024.
- When was Glixogen Therapeutics founded?
- Glixogen Therapeutics was founded in October 2018.
- Where is Glixogen Therapeutics headquartered?
- Glixogen Therapeutics is headquartered in Ness Ziona, Israel.
- Which investor participated in Glixogen Therapeutics' funding round?
- FutuRx participated in Glixogen Therapeutics' funding round in January 2019.
- What is Glixogen Therapeutics' employee count?
- Glixogen Therapeutics has an employee count in the 1-10 range.
- What technology does Glixogen Therapeutics utilize in its drug discovery?
- Glixogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1 to facilitate neuronal remyelination.
- Who are the founders of Glixogen Therapeutics?
- The founders of Glixogen Therapeutics are Dr. Yair Fisher (CSO) and Prof. James Salzer (Inventor).
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
biotechnologybiopharmaceuticalpharma-companiestherapeuticstreatmentsdegenerative-diseasesneurosciencedrug-discovery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/18974367 |
Identifiers & details
| Founded | 2018-10 |
|---|---|
| Status reason | Non Active, Dec 2024 ceased to operate |